The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of common inherited NOD2 mutations with exceptional response to immune checkpoint inhibitors.
 
Megan Babette Barnet
Research Funding - Pfizer
Patents, Royalties, Other Intellectual Property - NOD2
Other Relationship - Bristol Myers Squibb Foundation
 
Etienne Masle-Farquhar
No Relationships to Disclose
 
Amanda Russell
No Relationships to Disclose
 
Deborah Lilly Burnett
No Relationships to Disclose
 
Katherine J.L Jackson
No Relationships to Disclose
 
Robert Brink
No Relationships to Disclose
 
Gillian Heller
No Relationships to Disclose
 
Cindy Yang
No Relationships to Disclose
 
Stephenie Prokopec
No Relationships to Disclose
 
Andreas Behren
No Relationships to Disclose
 
Ian D. Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Medivation (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
 
Geoffrey D Peters
No Relationships to Disclose
 
Michael J. Boyer
Honoraria - AstraZeneca; CancerAid
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst)
Research Funding - Amgen (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Imugene (Inst); Janssen (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst)
 
Tom John
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech
Consulting or Advisory Role - Amgen (Inst); AstraZeneca; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; Ignyta; Merck KGaA; MSD Oncology; Novartis; Pfizer; PharmaMar (Inst); Roche/Genentech; Specialised Therapeutics
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche; Roche
 
Adnan Nagrial
No Relationships to Disclose
 
Bo Gao
Consulting or Advisory Role - BeiGene; IMPAC Medical Systems; IMPAC Medical Systems; MSD
 
Prunella Blinman
No Relationships to Disclose
 
Steven Chuan-Hao Kao
Honoraria - AstraZeneca; BMSi; MSD; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Pfizer
Research Funding - Pfizer
Travel, Accommodations, Expenses - AstraZeneca; BMSi; Roche
 
Jonathan S. Cebon
No Relationships to Disclose
 
Christopher Carl Goodnow
Research Funding - Pfizer
Patents, Royalties, Other Intellectual Property - Nod2